HCM
LGND icon

HMS Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

HMS Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-481
Closed -$30K – 150
2016
Q4 		$30K Buy
+481
New +$30.4K 0.03% 115

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

HMS Capital Management's LGND Position: Q2 2026 in Review

HMS Capital Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 2,520 shares worth $797K. The stake represents 0.3% of the portfolio and ranks #66 among its holdings. This is a return to the name: HMS Capital Management previously reported a position in LGND as recently as Q4 2016.

HMS Capital Management first reported a position in LGND in Q3 2016 and has held it in 3 quarters since. The position peaked at $1.06M in Q3 2016. 59 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • HMS Capital Management held 2,520 shares of Ligand Pharmaceuticals worth $797K as of Q2 2026.
  • Ligand Pharmaceuticals was a new HMS Capital Management position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.3% of HMS Capital Management's portfolio in Q2 2026, its #66 holding.
  • HMS Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 3 quarters since.
  • HMS Capital Management's Ligand Pharmaceuticals position peaked at $1.06M in Q3 2016.
  • 59 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on HMS Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.